What is the expected market price of Belumosudil by 2025?

Belumosudil mesylate tablets (Belumosudil) is the first ROCK2 inhibitor approved for the treatment of chronic graft-versus-host disease (cGVHD). Since its launch in the United States in 2021, it has quickly become an important breakthrough drug in the field of immune diseases. It improves the function of patients' skin, liver, lungs and other affected organs by regulating the balance of T cell subtypes, reducing inflammatory responses, and inhibiting tissue fibrosis. In addition to cGVHD, overseas research is also exploring its potential application in diseases such as systemic sclerosis, Crohn's disease, and idiopathic pulmonary fibrosis, showing extensive immunomodulatory potential.

In China, Besudil mesylate tablets have been officially launched and included in the national medical insurance catalog. The indications are mainly for patients with chronic graft-versus-host disease who have failed or relapsed after standard treatment. The domestic version is introduced and produced by Chinese pharmaceutical companies, and the specification is 0.2g*30 tablets. Due to high research and development costs and clinical value, its selling price before medical insurance ranges from RMB 10,000 to RMB 20,000 per box. After being included in medical insurance, the actual price paid by patients has dropped significantly, greatly improving accessibility.

In overseas markets, the original drugRezurock is produced by Kadmon Pharmaceuticals. The price of each box of 100mg*60 tablets is about US$10,000 to US$12,000, which is expensive. Some regions, such as Laos, India and Russia, have launched generic versions. The drug ingredients are basically the same as those of the original research. The price is significantly lower, about 4,000 yuan per box, making it an alternative choice for many multinational patients.

With the improvement of China's drug review and approval system and the promotion of the medical insurance negotiation mechanism, the clinical application scope and market acceptance of besudil are gradually expanding. In the future, this drug may be expanded to more immune fibrotic diseases and become an important part of the long-term management of chronic immune diseases.

Reference: https://www.drugs.com/pro/rezurock.html